NEA Management Company’s Zenas BioPharma ZBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$102M Hold
4,023,219
6.43% 7
2026
Q1
$78.7M Buy
4,023,219
+500,000
+14% +$11.2M 4.47% 8
2025
Q4
$128M Buy
3,523,219
+789,500
+29% +$26M 6.52% 6
2025
Q3
$60.7M Hold
2,733,719
3.33% 10
2025
Q2
$26.5M Buy
2,733,719
+119,771
+5% +$1.17M 1.99% 13
2025
Q1
$20.7M Hold
2,613,948
1.59% 13
2024
Q4
$21.4M Hold
2,613,948
1.21% 15
2024
Q3
$44.2M Buy
+2,613,948
New +$47M 2.41% 10

Other funds holding ZBIO

NEA Management Company's ZBIO Position: Q2 2026 in Review

NEA Management Company held its Zenas BioPharma (ZBIO) position steady in Q2 2026 at 4,023,219 shares worth $102M. The position accounts for 6.43% of the portfolio, ranked #7.

NEA Management Company first reported a position in ZBIO in Q3 2024 and has held it in 8 quarters since. The position peaked at $128M in Q4 2025. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • NEA Management Company held 4,023,219 shares of Zenas BioPharma worth $102M as of Q2 2026.
  • NEA Management Company left its Zenas BioPharma share count unchanged in Q2 2026.
  • Zenas BioPharma made up 6.43% of NEA Management Company's portfolio in Q2 2026, its #7 holding.
  • NEA Management Company first reported a position in Zenas BioPharma in Q3 2024 and has held it in 8 quarters since.
  • NEA Management Company's Zenas BioPharma position peaked at $128M in Q4 2025.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on NEA Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.